| 引用本文:侯莹，严波.补中益气汤联合xelox方案对晚期胃癌近期疗效和远期生存率的影响[J].世界中医药,2020,(03):. |
|
| 补中益气汤联合xelox方案对晚期胃癌近期疗效和远期生存率的影响 |
| Effects of Buzhong Yiqi Decoction Combined with XELOX Regimen on Short-term Efficacy and Long-term Survival Rate in Advanced Gastric Cancer |
| 投稿时间：2019-05-30 |
| DOI：10.3969/j.issn.1673-7202.2020.03.027 |
| 中文关键词: 晚期胃癌 补中益气汤 xelox 肿瘤标志物 生存率 |
| English Keywords:Advanced gastric cancer Buzhong Yiqi Decoction XELOX Tumor markers Survival rate |
| 基金项目:国家自然科学基金青年科学基金项目(81301947)——硝呋齐特增强负载肿瘤细胞裂解物DC疫苗抗肝癌效应研究 |
|
| 摘要点击次数: 568 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨补中益气汤联合xelox方案治疗晚期胃癌的近期疗效，及对远期生存情况的影响。方法：选取2013年2月至2016年2月溧水区人民医院收治的晚期胃癌患者90例作为研究对象，按照随机数表法分为对照组和观察组，每组45例。对照组患者接受xelox方案化疗、观察组接受xelox方案化疗＋补中益气汤治疗。比较2组患者的近期整体疗效、肿瘤标志物含量、用药安全性，治疗后随访2年并记录生存情况。结果：治疗后，观察组患者的有效率、疾病控制率高于对照组患者，差异有统计学意义（P<0.05）；血清中CA19-9、CA72-4、CA50、SF的含量低于对照组患者，差异有统计学意义（P<0.05）。2组患者治疗期间皮疹、恶心呕吐、肝功能损伤、骨髓抑制、感染等药物不良反应发生率比较，差异无统计学意义（P>0.05）。随访发现，观察组患者的1年生存率高于对照组患者，差异有统计学意义（P<0.05），组间2年生存率比较，差异无统计学意义（P>0.05）。结论：晚期胃癌患者在xelox化疗同时加入补中益气汤治疗，有助于提升近期疗效、延长远期生存率，且具有良好的用药安全性。 |
| English Summary: |
| To explore short-term efficacy of Buzhong Yiqi Decoction combined with XELOX regimen in the treatment of advanced gastric cancer, and its effects on long-term survival.Methods:A total of 90 cases of advanced gastric cancer patients treated in Lishui People's Hospital during February 2013 to February 2016 were selected as study objects and divided into control group and observation group by random number table method, with 45 cases in each group.Patients in the control group received XELOX regimen chemotherapy, and those in the observation group received XELOX regimen chemotherapy+Buzhong Yiqi Decoction.Short-term overall efficacy, contents of tumor markers and medication safety were compared between the 2 groups.The patients were followed up for 2 years and their survival was recorded.Results:After the treatment, the effective rate and disease control rate in the observation group were higher than those in the control group(P<0.05); serum contents of CA19-9, CA72-4, CA50 and SF were lower than those in the control group(P<0.05).There was no significant difference in incidences of adverse drug reactions such as rash, nausea and vomiting, liver function damage, bone marrow suppression and infection between the 2 groups during the treatment(P>0.05).Follow-up showed that the 1-year survival rate in the observation group was higher than that in the control group(P<0.05), and there was no significant difference in 2-year survival rate between the 2 groups(P>0.05).Conclusion:The combination of XELOX chemotherapy and Buzhong Yiqi Decoction is helpful to improve the short-term efficacy and prolong the long-term survival rate in patients with advanced gastric cancer, and has good medication safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
